Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07813208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival

Study acronym: RWD-Ph+ ALL
StatusRecruiting
PhaseNot specified
Started2025-08-01
View on ClinicalTrials.gov ↗
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
Trial Details
NCT Number NCT07813208
Lead Sponsor The Children's Hospital of Zhejiang University School of Medicine
Conditions Acute Lymphoblastic Leukemia, Pediatric
Enrollment 500 participants
Start Date 2025-08-01
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-10